Abstract
Phenylketonuria (PKU), a disease resulting in the disability to degrade phenylalanine (Phe) is an inborn error with a 1 in 10,000 morbidity rate on average around the world which leads to neurotoxicity. As an potential alternative to a protein-restricted diet, oral intake of engineered probiotics degrading Phe inside the body is a promising treatment, currently at clinical stage II (Isabella, et al., 2018). However, limited transmembrane transport of Phe is a bottleneck to further improvement of the probiotic’s activity. Here, we achieved simultaneous degradation of Phe both intracellularly and extracellularly by expressing genes encoding the Phe-metabolizing enzyme phenylalanine ammonia lyase (PAL) as an intracellularly free and a cell surface-immobilized enzyme in Escherichia coli Nissle 1917 (EcN) which overcomes the transportation problem. The metabolic engineering strategy was also combined with strengthening of Phe transportation, transportation of PAL-catalyzed trans-cinnamic acid and fixation of released ammonia. Administration of our final synthetic strain TYS8500 with PAL both displayed on the cell surface and expressed inside the cell to the PahF263S PKU mouse model reduced blood Phe concentration by 44.4% compared to the control EcN, independent of dietary protein intake. TYS8500 shows great potential in future applications for PKU therapy.
Article PDF
Similar content being viewed by others
References
Adolfsen, K.J., Callihan, I., Monahan, C.E., Greisen Per, J., Spoonamore, J., Momin, M., Fitch, L.E., Castillo, M.J., Weng, L., Renaud, L., et al. (2021). Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering. Nat Commun 12, 1–3.
Al Hafid, N., and Christodoulou, J. (2015). Phenylketonuria: a review of current and future treatments. Transl Pediatrics, 4, 304–317.
Bilder, D.A., Kobori, J.A., Cohen-Pfeffer, J.L., Johnson, E.M., Jurecki, E. R., and Grant, M.L. (2017). Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. Mol Genet Metab 121, 1–8.
Bourget, L., and Chang, T.M.S. (1989). Effects of oral administration of artificial cells immobilized phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. Biomater Artif Cells Artif Organs 17, 161–181.
Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248–254.
Cao, Y., Song, M., Li, F., Li, C., Lin, X., Chen, Y., Chen, Y., Xu, J., Ding, Q., and Song, H. (2019). A synthetic plasmid toolkit for Shewanella oneidensis MR-1. Front Microbiol 10, 410.
Chang, T.M.S. (2005). Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discov 4, 221–235.
Durrer, K.E., Allen, M.S., and Hunt von Herbing, I. (2017). Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLoS ONE 12, e0176286.
Duydu, Y., SÜZen, S., Vural, N., Erdem, N., Uysal, H. (1999). A modified method for determination of hippuric acid in urine by HPLC. Ankara Universitesi Eczacilik Fakultesi Dergisi, 28, 37–46.
Goormans, A.R., Snoeck, N., Decadt, H., Vermeulen, K., Peters, G., Coussement, P., Van Herpe, D., Beauprez, J.J., De Maeseneire, S.L., and Soetaert, W.K. (2020). Comprehensive study on Escherichia coli genomic expression: does position really matter? Metab Eng 62, 10–19.
Hoskins, J.A., and Gray, J. (1982). Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans. Res Commun Chem Pathol Pharmacol, 35, 275–282.
Hoskins, J.A., Holliday, S.B., and Greenway, A.M. (1984). The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study. Biol Mass Spectrom 11, 296–300.
Hoskins, J.A., Jack, G., Peiris, R.J.D., Starr, D.J.T., Wade, H.E., Wright, E. C., and Stern, J. (1980). Enzymatic control of phenylalanine intake in phenylketonuria. Lancet 315, 392–394.
Huisman, G.W., Agard, N.J., Mijts, B., Vroom, J., Zhang, X., Huisman, G., and Agard, N. (2014). New engineered polypeptide useful in pharmaceutical composition for treating phenylketonuria, has phenylalanine ammonia-lyase (PAL) activity, comprises specific amino acid sequence. US Patent, 2014314843-A1.
Hydery, T., and Coppenrath, V.A. (2019). A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria. Drug Target Insights 13.
Hyun, M.W., Yun, Y.H., Kim, J.Y., and Kim, S.H. (2011). Fungal and plant phenylalanine ammonia-lyase. Mycobiology 39, 257–265.
Isabella, V.M., Ha, B.N., Castillo, M.J., Lubkowicz, D.J., Rowe, S.E., Millet, Y.A., Anderson, C.L., Li, N., Fisher, A.B., West, K.A., et al. (2018). Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol 36, 857–864.
Kang, D.G., Li, L., Ha, J.H., Choi, S.S., and Cha, H.J. (2008). Efficient cell surface display of organophosphorous hydrolase using N-terminal domain of ice nucleation protein in Escherichia coli. Korean J Chem Eng 25, 804–807.
Kurtz, C.B., Millet, Y.A., Puurunen, M.K., Perreault, M., Charbonneau, M. R., Isabella, V.M., Kotula, J.W., Antipov, E., Dagon, Y., Denney, W.S., et al. (2019). An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci Transl Med 11, eaau797.
Lee, S.Y., Choi, J.H., and Xu, Z. (2003). Microbial cell-surface display. Trends Biotechnol 21, 45–52.
Levy, H.L., Sarkissian, C.N., and Scriver, C.R. (2018). Phenylalanine ammonia lyase (PAL): from discovery to enzyme substitution therapy for phenylketonuria. Mol Genet Metab 124, 223–229.
Li, Q., Sun, B., Chen, J., Zhang, Y., Jiang, Y., and Yang, S. (2021). A modified pCas/pTargetF system for CRISPR-Cas9-assisted genome editing in Escherichia coli. Acta Biochim Biophys Sin 53, 620–627.
Liang, B., Li, L., Mascin, M., and Liu, A. (2012). Construction of xylose dehydrogenase displayed on the surface of bacteria using ice nucleation protein for sensitive D-xylose detection. Anal Chem 84, 275–282.
Markham, A. (2018). Pegvaliase: first global approval. BioDrugs 32, 391–395.
Mays, Z.J., Mohan, K., Trivedi, V.D., Chappell, T.C., and Nair, N.U. (2020). Directed evolution of Anabaena variabilis phenylalanine ammonia-lyase (PAL) identifies mutants with enhanced activities. Chem Commun 56, 5255–5258.
Narita, J., Okano, K., Tateno, T., Tanino, T., Sewaki, T., Sung, M.H., Fukuda, H., and Kondo, A. (2006). Display of active enzymes on the cell surface of Escherichia coli using PgsA anchor protein and their application to bioconversion. Appl Microbiol Biotechnol 70, 564–572.
Puurunen, M.K., Vockley, J., Searle, S.L., Sacharow, S.J., Phillips Iii, J.A., Denney, W.S., Goodlett, B.D., Wagner, D.A., Blankstein, L., Castillo, M.J., et al. (2021). Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nat Metab 3, 1125–1132.
Qu, W., Xue, Y., and Ding, Q. (2015). Display of fungi xylanase on Escherichia coli cell surface and use of the enzyme in xylan biodegradation. Curr Microbiol 70, 779–785.
Ravirala, R.S., Barabote, R.D., Wheeler, D.M., Reverchon, S., Tatum, O., Malouf, J., Liu, H., Pritchard, L., Hedley, P.E., Birch, P.R.J., et al. (2007). Efflux pump gene expression in Erwinia chrysanthemi is induced by exposure to phenolic acids. Mol Plant Microbe Interact 20, 313–320.
Sarkissian, C.N., Shao, Z., Blain, F., Peevers, R., Su, H., Heft, R., Chang, T. M.S., and Scriver, C.R. (1999). A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci USA 96, 2339–2344.
Smith, N., Longo, N., Levert, K., Hyland, K., and Blau, N. (2019). Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. Mol Genet Metab 126, 406–412.
Sonnenborn, U. (2016). Escherichia coli strain Nissle 1917—from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol Lett 363, fnw212.
Yin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al. (2022). Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor. Sci China Life Sci 65, 718–730.
van Spronsen, F.J. (2010). Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol 6, 509–514.
Zhang, Y., Jia, X., Wang, L., Liu, J., and Ma, G. (2011). Preparation of Ca-Alginate microparticles and its application for phenylketonuria oral therapy. Ind Eng Chem Res 50, 4106–4112.
Zhang, Z., Tang, R., Bian, L., Mei, M., Li, C., Ma, X., Yi, L., and Ma, L. (2016). Surface immobilization of human arginase-1 with an engineered ice nucleation protein display system in E. coli. PLoS ONE 11, e0160367.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (21825804, 31921006), the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China (2018ZX09711002-019), the Shanghai Municipal Science and Technology Major Project and the National Key Research and Development Program of China (2018YFA0800603). The authors would like to acknowledge Dr. Shuming Yin and Prof. Dali Li from Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University for providing PKU animal models in the early stage of the project. We also thank Dr. Xinwen Huang from The Children’s Hospital, Zhejiang University School of Medicine for helpful discussion on the clinical potential of the project. We also thank Jieze Zhang from the Department of Chemistry, University of Southern California for language editing of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Compliance and ethics
The author(s) declare that they have no conflict of interest. Shanghai Taoyusheng Biotechology Co., Ltd. has commercial interest in the project. All animal work conformed to the regulations of the animal ethics committee and was approved by Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences for Animal Research.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Jiang, Y., Sun, B., Qian, F. et al. Expression of phenylalanine ammonia lyase as an intracellularly free and extracellularly cell surface-immobilized enzyme on a gut microbe as a live biotherapeutic for phenylketonuria. Sci. China Life Sci. 66, 127–136 (2023). https://doi.org/10.1007/s11427-021-2137-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-021-2137-3